alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 87, Number 44 (Monday, March 7, 2022)]
[Notices]
[Page 12716]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04752]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Special Topics: Machine Learning and Artificial Intelligence 
Analysis of OCT and Related Modalities for Ocular Diseases.
    Date: March 16, 2022.
    Time: 3:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Susan Gillmor, Ph.D., Scientific Review Officer, 
National Institutes of Health, Center for Scientific Review, 6701 
Rockledge Drive, Bethesda, MD 20892, (240) 762-3076, 
<a href="/cdn-cgi/l/email-protection#9ae9efe9fbf4b4fdf3f6f6f7f5e8daf4f3f2b4fdf5ec"><span class="__cf_email__" data-cfemail="5c2f292f3d32723b35303031332e1c323534723b332a">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: March 2, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-04752 Filed 3-4-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
August 15, 2011

Mr. Raymond Towles 

Acting Director, Flight Standards 

Federal Aviation Administration 

800 Independence Ave. SW 

Washington, DC 20591 

Dear Mr. Towels: 

Thank you for your letter dated Oct 1, 2010 in reference to our request for an exemption from 

§141.5(d) of Title 14, Code of Federal Regulations. You stated in your letter that the relief we are 

seeking is now covered under the amended regulation. Because of the wording in the revised 

amendment, our POI and FSDO still have a problem in renewing our 141 certificate. They have 

instructed me to return to your office for clarification. 

The revised amendment reads in pertinent part: (emphasis added) 

 (d) Has established a pass rate of 80 percent or higher on the first attempt for all 

 knowledge test leading to a certificate or rating, practical tests leading to a certificate or 

 rating, or end-of-course tests for an approved training course specified in appendix K

 of this part. 

All of the courses offered by RTC use FTD’s only. Therefore, our pilot refresher courses are part 

141.57 Special Curricula and may not technically be in appendix K. RTC’s training courses 

contain features that achieve a level of pilot proficiency equivalent to the Pilot Refresher Course 

in appendix K. (See enclosed TCO.) 

The intent of 141.5(d) is to measure the quality of training. It is also apparent that if an approved 

course leads to certification or a rating, then the test must be the official FAA knowledge test or 

the official FAA practical test in the PTS. However, in the case where a course does not lead to a 

rating, there is no official FAA test. This leaves only an end of course test to measure quality 

from. It should also be noted that 141.5(d) uses the words for all indicating that all approved 

courses need to be tested under the quality of training aspect. 

So could our end of course test be used to meet the requirement of 141.5(d), or do we need to 

continue with the exemption process? 

Thank you, 

John Killeen, 

President 

Ps. I have also included a copy of our request for exemption in case you no longer have it. 

Enclosures
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET, CONSOLIDATED STATEMENT OF OPERATIONS AND
CONSOLIDATED STATEMENT OF CASH FLOWS INCLUDED IN THE COMPANY'S FORM 10-KSB FOR
THE YEAR ENDED SEPTEMBER 30, 2000, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          SEP-30-2000
<PERIOD-START>                             OCT-01-1999
<PERIOD-END>                               SEP-30-2000
<CASH>                                       3,228,382
<SECURITIES>                                         0
<RECEIVABLES>                                  397,595
<ALLOWANCES>                                   (4,138)
<INVENTORY>                                          0
<CURRENT-ASSETS>                             3,888,586
<PP&E>                                       6,774,849
<DEPRECIATION>                               (878,685)
<TOTAL-ASSETS>                               9,881,646
<CURRENT-LIABILITIES>                        1,065,392
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                        565
<COMMON>                                        16,905
<OTHER-SE>                                   8,798,784
<TOTAL-LIABILITY-AND-EQUITY>                 9,881,646
<SALES>                                      1,411,567
<TOTAL-REVENUES>                             1,411,567
<CGS>                                          738,782
<TOTAL-COSTS>                                2,187,267
<OTHER-EXPENSES>                            10,580,016
<LOSS-PROVISION>                               (4,138)
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                           (11,858,546)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                       (11,858,546)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (11,858,546)
<EPS-BASIC>                                     (1.87)
<EPS-DILUTED>                                   (1.87)


</TABLE>
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 01-60090 Summary Calendar

LARRY ROCHELL SMITH, Plaintiff-Appellant,

versus DON GRANT, Warden of Delta Correctional Facility; OHAMZAH BRIMAH, Doctor and Psychiatrist at Delta Correctional Facility, Defendants-Appellees.

- - - - - - - - - - Appeal from the United States District Court for the Northern District of Mississippi

USDC No. 4:99-CV-272-D-D

- - - - - - - - - - December 14, 2001 Before DAVIS, BENAVIDES and STEWART, Circuit Judges.
PER CURIAM: * Larry Rochell Smith, Mississippi prisoner # 89754, appeals from the district court’s order granting summary judgment in favor of the defendants in Smith’s civil rights complaint brought pursuant to 42 U.S.C. § 1983. Smith argues that the appellees were deliberately indifferent to his serious medical needs because: 1) the Delta Correctional Facility (DCF) is not a medically adequate or proper facility in which to incarcerate him because of his mental condition; and 2) the treatment andNo. 01-60090 -2- medications he received at DCF were inadequate to fully address his mental condition. We have reviewed the record and the briefs of the parties, and we conclude that the district court committed no reversible error. Smith’s allegations do not meet his burden of producing evidence showing the existence of a genuine issue for trial regarding deliberate indifference because they amount to no more than disagreement with his medical treatment, a claim not actionable under 42 U.S.C. § 1983. See Varnado v. Lynaugh , 920 F.2d 320, 321 (5th Cir. 1991). Accordingly, the district court’s judgment is AFFIRMED.
<PAGE>
                                                                    EXHIBIT 10.4



                               AMENDMENT NO. 1 TO
                              EMPLOYMENT AGREEMENT

         This Amendment No. 1 to Employment Agreement is made as of this 1st day
of April, 2002, by and between Stewart Enterprises, Inc., a Louisiana
corporation (the "Company"), and Lawrence B. Hawkins (the "Employee").

                                   WITNESSETH:

         WHEREAS, the Company has entered into an Employment Agreement with the
Employee dated as of November 1, 2001 (the "Employment Agreement"); and

         WHEREAS, the Company and the Employee have agreed to eliminate certain
benefits payable to Employee upon termination of employment in consideration of
the inclusion of Employee as an initial participant in a Supplemental Executive
Retirement Plan (the "SERP").

         NOW, THEREFORE, for and in consideration of the continued employment of
Employee by the Company, the payment of wages, salary and other compensation to
Employee by the Company and the benefits potentially payable to Employee under
the SERP, the parties hereto agree as follows, effective as of April 1, 2002:

         SECTION 1. Except as expressly amended herein, all of the terms and
provisions of the Employment Agreement shall remain in full force and effect.

         SECTION 2. Article IV, Section 5 of the Employment Agreement is hereby
deleted in its entirety.

         SECTION 3. Article IV, Section 6 of the Employment Agreement is hereby
renumbered as Article IV, Section 5.

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed and signed as of the date indicated above.

                               STEWART ENTERPRISES, INC.


                               By:
                                  ----------------------------------------
                                        James W. McFarland
                                        Compensation Committee Chairman

                               EMPLOYEE:


                               -------------------------------------------
                                          Lawrence B. Hawkins
MEMORANDUM

DATE: 09/19/2014

FROM: Laura Farris/EPA Region 8

TO: Clean Power Plan for Existing Power Plants; Docket Id: OAR–2013-0602

SUBJECT: Montana PSC Conference Call held on 09/19/2014

SUMMARY: 

At the request of Travis Kavulla, Commissioner, Montana Public Service Commission (PSC), staff from 

EPA Headquarters, EPA Region 8, and EPA Region 9 participated in a conference call with the Montana 

PSC and others on EPA’s use of the integrated planning model (IPM) for the Clean Power Plan on 

09/19/2014. The Clean Power Plan was proposed on June 2, 2014.

ATTENDEES:

EPA Headquarters

Gabrielle Stevens, Bill Meroney, Brian Fisher, Reid Harvey, Mikhail Adamantiades, Jeb Stenhouse, 

Jeremy Mark

EPA Region 8

Laura Farris

EPA Region 9

Ben Machol

External Stakeholders

Commissioner, Travis Kavulla, Margo Schurman and Bob Decker, Montana PSC

Peter Ashcroft, Utah Office of Energy Development

Keegan Moyer, Western Electricity Coordinating Council

Tom Carr and Alaine Ginocchio, Western Interstate Energy Board

Karen Griffin, Grace Anderson, and Angela Tanghetti, California Energy Commission

Ed Stoneburg, Arizona Corporation Commission

Questions Discussed

(1) We've heard from RTOs some criticism of the deficiency of IPM as a hub-and-spoke model that 

doesn't accurately represent regions but instead uses NERC regions, which do not represent current 

market footprints. Could IPM explain how it defines regions and uses them in its model? 

(2) A fuller explanation of what it is meant to be a 'hub-and-spoke' model 

(3) A description of how transmission is modeled, or could be modeled/assumed as a supplement to 

modeling results. (On this point, thinking of the utilization, load-duration, and power flow studies 

that certain NERC designated Regional Entities engage in.)

(4) A description of the source data for cost analysis. 

(5) What is the time-period granularity of the model (some software represents dispatch on an hourly 

basis, others on an intra-hourly basis) 

(6) How does the model incorporate, if at all, stochasticity and the quantification of uncertainty as users 

are asked to feed in assumptions to populate the model.
#### UNITED STATES of America, Plaintiff-Appellee v. Alfredo ESCOBAR, Defendant-Appellant

No. 16-11755 Conference Calendar

United States Court of Appeals, Fifth Circuit.

Filed August 18, 2017

James Wesley Hendrix, Assistant U.S. Attorney, U.S. Attorney’s Office, Northern District of Texas, Dallas, TX, for Plaintiff-Appellee • •

Alfredo Escobar, Pro Se

Before JOLLY, HIGGINBOTHAM, and ELROD, Circuit Judges.

PER CURIAM: *

The Federal Public Defender appointed to represent Alfredo Escobar has moved for leave to withdraw and has filed a brief in accordance with *Anders v. California,*386 U.S. 738, 87 S.Ct. 1396, 18 L.Ed.2d 493 (1967), and *United States v. Flores,*632 F.3d 229 (5th Cir. 2011). Escobar has not filed a response. We have reviewed counsel’s brief and the relevant portions of the record reflected therein. We concur with counsel’s assessment that the appeal presents no nonfrivolous issue for appellate review. Accordingly, counsel’s motion for leave to withdraw is GRANTED, counsel is excused from further responsibilities herein, and the APPEAL IS DISMISSED. *See*6th Cir. R. 42.2.

*

 Pursuant to 5th Cir. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Cir. R. 47.5.4.
**EXHIBIT 8.1**

**List of Subsidiaries**

Significant Subsidiaries: 

Home Inns & Hotels Management (Hong Kong) Limited – Incorporated in Hong Kong 

Hong Kong Ai Home InvestmentCompany – Incorporated in Hong Kong 

Hemei Hotel Management Company – Incorporated in the PRC 

Home Inns & Hotels Management (Beijing) Co., Ltd. – Incorporated in the PRC 

Home Inns Hotel Management (Shanghai) Co., Ltd. – Incorporated in the PRC 

Shanghai Chuwen Investment Holding Co.,Ltd. – Incorporated in the PRC 

Shanghai Top Star Hotel Management Co., Ltd. – Incorporated in the PRC
I 

118TH CONGRESS 

1ST SESSION H. R. 704 

To amend title XVIII of the Social Security Act to permit nurse practitioners 

and physician assistants to satisfy the documentation requirement under 

the Medicare program for coverage of certain shoes for individuals with 

diabetes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 1, 2023 

Mr. BLUMENAUER (for himself and Mr. LAHOOD) introduced the following 

bill; which was referred to the Committee on Energy and Commerce, and 

in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of 

such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To amend title XVIII of the Social Security Act to permit 

nurse practitioners and physician assistants to satisfy 

the documentation requirement under the Medicare program for coverage of certain shoes for individuals with 

diabetes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Promoting Access to 

5 Diabetic Shoes Act’’. 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 704 IH

1 SEC. 2. PERMITTING NURSE PRACTITIONERS AND PHYSI2 CIAN ASSISTANTS TO SATISFY MEDICARE 

3 DOCUMENTATION REQUIREMENT FOR COV4 ERAGE OF CERTAIN SHOES FOR INDIVIDUALS 

5 WITH DIABETES. 

6 Section 1861(s)(12) of the Social Security Act (42 

7 U.S.C. 1395x(s)(12)) is amended— 

8 (1) in subparagraph (A), by inserting ‘‘, nurse 

9 practitioner, or physician assistant’’ after ‘‘physi10 cian’’; and 

11 (2) in subparagraph (C), by inserting ‘‘, nurse 

12 practitioner, or physician assistant’’ after each oc13 currence of ‘‘physician’’. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS
**EXHIBIT
      32.1**




**Certification
      of**


**Chief
      Executive Officer**


**of
      Buckeye Ventures, Inc. Pursuant to**


**Section
      906 of the Sarbanes-Oxley Act of 2002**




This
      certification is furnished solely pursuant to Section 906 of the Sarbanes-Oxley
      Act of 2002 (18 U.S.C. 1350) and accompanies the Quarterly Report on Form 10-QSB
      (the “Form 10-QSB”) for the three months ended March 31, 2007, of Buckeye
      Ventures, Inc. (the “Company”).  I, Alan J. Mintz, the Chief Executive
      Officer of the Company, certify that, to the best of my knowledge:




(1)
            The
                Form 10-QSB fully complies with the requirements of section 13(a)
                or
                section 15(d) of the Securities Exchange Act of 1934;
                and




(2)
            The
                information contained in the Form 10-QSB fairly presents, in all
                material
                respects, the financial condition and results of operations of the
                Company.




The
      foregoing certification is being furnished as an exhibit to the Form 10-QSB
      pursuant to Item 601(6)(32) of Regulation S-B and Section 906 of the
      Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter
      63
      of Title 18, United States Code) and, accordingly, is not being filed as part
      of
      the Form 10-QSB for purposes of Section 18 of the Securities Exchange Act of
      1934, as amended, and is not incorporated by reference into any filing of the
      registrant, whether made before or after the date hereof, regardless of any
      general incorporation language in such filing.




Date:
                May 15, 2007
            
            By:
            /s/
                Alan J. MintzAlan
                J. MintzPresident
                and Chief Executive Officer(Principal
                Executive Officer)
#### In the Matter of the Arbitration between Kahn *&*Feldman, Inc., Respondent, and Louis F. Rothschild et al., Appellants.

Argued April 7, 1943;

decided May 27, 1943.

*782
      *Barney B. Fensterstock*and *Harry Zalkin*for appellants.

*Jerome L. Greene*for respondent.

Order affirmed, with costs; no opinion.

Concur: Loughran, Rippey, Lewis, Conway and Desmond, JJ. Taking no part: Lehman, Ch. J., and Finch, J.
Exhibit 99.1

                            CERTIFICATION PURSUANT TO
                              18 USC, SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


     In  connection  with the  annual  report  of  SAMESSA  HOLDING  CORP.  (the
"Company")  on Form 10-KSB for the fiscal year ended  March 31,  2002,  as filed
with the Securities and Exchange Commission (the "Report"), I, Andrew I. Telsey,
the Chief  Executive  Officer and the Chief  Financial  Officer of the  Company,
certify,  pursuant to Section 906 of the  Sarbanes-Oxley  Act of 2002 (18 U.S.C.
Section 1350), that to the best of my knowledge:


     1.   The Report fully  complies with the  requirements  of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     2.   The  information  contained  in the  Report  fairly  presents,  in all
          material respects,  the financial  condition and results of operations
          of the Company.




Dated: January 15, 2003                    s/Andrew I. Telsey
                                           -------------------------------------
                                           Chief Executive Officer and
                                           Chief Financial Officer

















                                                                              26
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6903 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                H. R. 6903

   To direct the Secretary of Defense to develop a plan to ensure an 
     adequate supply of medications for the military health system.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           December 22, 2023

 Ms. Slotkin (for herself and Mr. Gallagher) introduced the following 
      bill; which was referred to the Committee on Armed Services

_______________________________________________________________________

                                 A BILL

 
   To direct the Secretary of Defense to develop a plan to ensure an 
     adequate supply of medications for the military health system.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Stockpiling Active Pharmaceutical 
Ingredients Act''.

SEC. 2. DEVELOPMENT OF PLAN TO ENSURE AN ADEQUATE SUPPLY OF MEDICATIONS 
              FOR THE MILITARY HEALTH SYSTEM.

    Not later than one year after the date of the enactment of this 
Act, the Secretary of Defense shall develop a plan, regarding the 
military health system--
            (1) for stockpiling essential medications to ensure 
        availability of a 180-day supply during armed conflict or other 
        supply chain disruptions; and
            (2) that mitigates vulnerabilities to active pharmaceutical 
        ingredient supply chains and reduces dependence on active 
        pharmaceutical ingredients from foreign sources.
                                 <all>
```